Apollomics (NASDAQ:APLM) Price Target Cut to $2.00 by Analysts at HC Wainwright

Apollomics (NASDAQ:APLM) had its price objective reduced by HC Wainwright from $5.00 to $2.00 in a report released on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock.

Apollomics Stock Performance

NASDAQ:APLM opened at $0.41 on Wednesday. The company’s fifty day moving average price is $0.58 and its 200-day moving average price is $0.74. Apollomics has a 1-year low of $0.39 and a 1-year high of $6.45.

Hedge Funds Weigh In On Apollomics

A hedge fund recently bought a new stake in Apollomics stock. Powell Investment Advisors LLC purchased a new stake in Apollomics, Inc. (NASDAQ:APLM) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 130,297 shares of the company’s stock, valued at approximately $98,000. Powell Investment Advisors LLC owned 0.15% of Apollomics at the end of the most recent quarter. Institutional investors and hedge funds own 19.13% of the company’s stock.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.